Human Spleen: Formalin-Fixed, Paraffin-Embedded (FFPE)

PathPlus™ CD79A / CD79 Alpha Antibody (aa202-216, clone IGA/1688R)

Primary AntibodyLSBio Guarantee

Antibody:	Rabbit Recombinant Monoclonal
Applications:	Flow Cytometry, Immunofluorescence, Immunohistochemistry (general), Immunohistochemistry, Paraffin, Western Blot
Reactivity:	Human
Format:	Liquid

See all CD79A / CD79 Alpha antibodies â†’

$536.00each

Catalog Number: LS-B16269-100

Unit Size

Quantity

For bulk orders or custom formulations:

Overview

Description: CD79 Alpha antibody LS-B16269 is an unconjugated rabbit recombinant monoclonal antibody to human CD79 Alpha (CD79A) (aa202-216). Validated for Flow, IF, IHC and WB.
Application: FC, IF, IHC, IHC-P, WB
Reactivity: Hu
Intended Use: Research Use Only
Guarantees: This product carries the LSBio 100% Guarantee. ✓
Category: Antibodies > Primary Antibodies > Recombinant Antibodies
Alternative Names: CD79a antigen | CD79A | Ig-alpha | MB-1 | MB-1 membrane glycoprotein | Surface IgM-associated protein | MB1
Recommended Dilution: FC: 1 - 2 µg/10E6 cells
Recommended Dilution: IF/ICC: 1 - 2 µg/ml
Recommended Dilution: IHC-P: 1:100
Recommended Dilution: WB: 1 - 2 µg/ml
UniProt Number: P11912
NCBI GenBank: NM_021601 | NP_001774.1
SwissProt: P11912

Target

Target: CD79A / CD79 Alpha
Antigen Species: Human
Specificity: A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.
Epitope: A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.
Gene Name: CD79A